Cor Vasa 2007, 49(10):K286

Stránka k zamyšlení: Ananda

Published: October 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Stránka k zamyšlení: Ananda. Cor Vasa. 2007;49(10):K286.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Reaven GM. Non-insulin-dependent diabetes mellitus, abnormal lipoprotein metabolism, and atherosclerosis. Metabolism 1987; 36 (Suppl 1):1-8. Go to original source... Go to PubMed...
    2. Šochman J. Nemoc tučných jater a statiny - kterému oboru patří tento problém? Čas Lék čes 2006;145:443-6.
    3. Hradec J. Endokanabinoidní systém - nový léčebný cíl u multirizikových nemocných. Remedia 2005;15:163-8.
    4. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. RIO-North America Study Group. Effect of rimonabant, a cannabionoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-75. Go to original source... Go to PubMed...
    5. Despres JP, Golay A, Sjostrom L. Rimonabant in Obesity-Lipids Study group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New Engl J Med 2005;353:2121-34. Go to original source... Go to PubMed...

    Return to the content